Epigenetic biomarkers for human cancer: the time is now.
about
Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancerToxicogenomic profiling of chemically exposed humans in risk assessmentDNA methylation profiling revealed promoter hypermethylation-induced silencing of p16, DDAH2 and DUSP1 in primary oral squamous cell carcinomaThe clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancerAberrant DNA methylation in cervical carcinogenesisVariation in the large-scale organization of gene expression levels in the hippocampus relates to stable epigenetic variability in behaviorIncorporating epigenetic data into the risk assessment process for the toxic metals arsenic, cadmium, chromium, lead, and mercury: strategies and challengesMethylation of the CpG sites only on the sense strand of the APC gene is specific for hepatocellular carcinomaAmyloid Beta-Mediated Hypomethylation of Heme Oxygenase 1 Correlates with Cognitive Impairment in Alzheimer's DiseasePromoter methylation of IGFBP-3 and p53 expression in ovarian endometrioid carcinoma.Array-based DNA methylation profiling for breast cancer subtype discrimination.Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer.Pathology tissue-chromatin immunoprecipitation, coupled with high-throughput sequencing, allows the epigenetic profiling of patient samples.Gene methylation as a powerful biomarker for detection and screening of non-small cell lung cancer in blood.Circadian rhythm and its role in malignancyMessenger RNA expression and methylation of candidate tumor-suppressor genes and risk of ovarian cancer-a case-control analysisThe promoter methylation status and mRNA expression levels of CTCF and SIRT6 in sporadic breast cancerA gene panel, including LRP12, is frequently hypermethylated in major types of B-cell lymphoma.Clinical potential of DNA methylation in gastric cancer: a meta-analysis.Diagnostic biomarkers are hidden in the infected host's epigenome.Quantification of 5-methylcytosine, 5-hydroxymethylcytosine and 5-carboxylcytosine from the blood of cancer patients by an enzyme-based immunoassay.Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma.DNA methylation epigenotypes in breast cancer molecular subtypes.Promoter hypermethylation of tumour suppressor genes as potential biomarkers in colorectal cancer.Infant growth restriction is associated with distinct patterns of DNA methylation in human placentas.Cancer epigenetics: linking basic biology to clinical medicine.Transcriptional implications of intragenic DNA methylation in the oestrogen receptor alpha gene in breast cancer cells and tissues.Differential methylation of the promoter and first exon of the RASSF1A gene in hepatocarcinogenesis.DNA methylation profiling in Barrett's esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclassesHeterochromatin protein 1alpha: a hallmark of cell proliferation relevant to clinical oncology.DNA methylation based biomarkers in non-invasive cancer screening.Transgelin gene is frequently downregulated by promoter DNA hypermethylation in breast cancer.Advances in biomarker research for pancreatic cancer.Direct reprogramming by oncogenic Ras and Myc.Promoter hypermethylation in male breast cancer: analysis by multiplex ligation-dependent probe amplification.Quantitative proteomic analysis of histone modifications in decitabine sensitive and resistant leukemia cell linesNormal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype.Epigenetics, oxidative stress, and Alzheimer disease.Integrated genomic analysis of breast cancers.Minireview: epigenetic changes in ovarian cancer.
P2860
Q21260388-858593F2-22BA-4DBB-B1B4-232DFE63C9C2Q24289420-6B386B25-420C-4AB2-8EB2-1EF271ECC227Q24606042-685FD022-B2BF-4611-A01A-4B68E7127F9BQ26766285-52975DFD-5E12-4C3F-871A-7973EBEF5FADQ26830289-620C761A-44B7-4C44-A368-D8F643ADFD71Q27438170-869A6B08-08C4-4F4F-BBCE-442327E47F16Q28390395-D4A0E7CA-4115-4247-82FE-13E9950F99BAQ28743228-37480FD7-B257-40D4-80C1-C9EE178C4F11Q30385357-7BA19C3C-76BC-4753-9D6F-87EBAA700A25Q33562658-5774D33C-96D2-451D-9EDA-303E787FA7DBQ33689442-4C52F79B-262A-4A75-B1BD-CC69D0DDB1DDQ33690321-60DBAFAA-936E-4298-89A1-2CA7DAA12B09Q33755701-A0769ABF-6495-4028-95B8-63B96FF7E91BQ33761873-0B212D64-63EF-4239-880F-9E4FB0138E99Q33784815-9686ABD1-3016-454C-B980-983857DF805FQ34044661-18395B60-5550-41C3-864F-CCEFD9D3A20FQ34088277-1A556C33-6389-4444-8FD8-6332F645B8F3Q34194620-9AE4E23D-795A-4F16-BAAB-2FEAF90CBB0DQ34257393-11F646E3-A126-44B7-8FC7-9148D3015244Q34360404-8D7808D3-DCDC-4425-A6FA-F63BFA33FC3BQ34625614-6AA72601-B226-4FAD-BB95-DFFA6D3F639FQ34750551-C7F67013-D2A4-43E5-8CAF-BFF3CEEBFF28Q34989097-FD42D469-35E8-4D32-A59F-F5E857DE4A72Q35138892-1894C3AC-B205-4558-97E3-CF2FA07C4F75Q35159055-D8775747-D90F-4EA9-9824-EDBDDEFD76DBQ35348043-91236D08-5F3D-47DF-AEA7-D5325A96441FQ35585074-5752AB1E-C6F7-4554-9D3B-2F95FE2F0DD9Q35589600-EE97258F-4A4D-4FEF-9F9A-9DBA2E23A169Q35667377-698BEF22-27CB-4450-BBFC-85C56CF625F3Q36042059-7818C9B2-38FD-4110-BE2D-B57A01A316B9Q36095878-0B4F1FE6-2A1F-4B56-AEC4-04435B2C4FEFQ36105177-9DE7BB33-5D9C-4C9B-BAEF-7DEE10BDF115Q36126609-3353F3DA-09DF-4C94-87F9-96B22B2D36C8Q36673216-F0D1D9B2-C1A4-4626-90BD-93819FA3AEA9Q36924432-5315820A-9FF1-4473-BA14-141DF8CC9EA0Q37064586-EE48A594-0497-478F-8D05-1DE614292D53Q37162103-6B49FBD1-D93E-4B6B-836D-58ECEB699A5FQ37169854-2984C079-7060-4E9A-8243-B71C93EC7E2FQ37181531-844F890C-6C65-4BE7-ABEA-683DF12CA92AQ37328836-EBB29036-D9F4-4C58-A76A-B447E44C8FF6
P2860
Epigenetic biomarkers for human cancer: the time is now.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Epigenetic biomarkers for human cancer: the time is now.
@en
Epigenetic biomarkers for human cancer: the time is now.
@nl
type
label
Epigenetic biomarkers for human cancer: the time is now.
@en
Epigenetic biomarkers for human cancer: the time is now.
@nl
prefLabel
Epigenetic biomarkers for human cancer: the time is now.
@en
Epigenetic biomarkers for human cancer: the time is now.
@nl
P1476
Epigenetic biomarkers for human cancer: the time is now.
@en
P2093
Sonia Mulero-Navarro
P356
10.1016/J.CRITREVONC.2008.03.001
P577
2008-04-21T00:00:00Z